Browsing by Author "Fatimawali"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Hormonal Therapy for Gynecological Cancers
    (Daffodil International University, 2022-02-01) Mitra, Saikat; Lami, Mashia Subha; Ghosh, Avoy; Das, Rajib; Tallei, Trina Ekawati; Fatimawali; Islam, Fahadul; Dhama, Kuldeep; Begum, M Yasmin; Aldahish, Afaf; Chidambaram, Kumarappan; Emran, Talha Bin
    In recent years, hormone therapy has been shown to be a remarkable treatment option for cancer. Hormone treatment for gynecological cancers involves the use of medications that reduce the level of hormones or inhibit their biological activity, thereby stopping or slowing cancer growth. Hormone treatment works by preventing hormones from causing cancer cells to multiply. Aromatase inhibitors, anti-estrogens, progestin, estrogen receptor (ER) antagonists, GnRH agonists, and progestogen are effectively used as therapeutics for vulvar cancer, cervical cancer, vaginal cancer, uterine cancer, and ovarian cancer. Hormone replacement therapy has a high success rate. In particular, progestogen and estrogen replacement are associated with a decreased incidence of gynecological cancers in women infected with human papillomavirus (HPV). The activation of estrogen via the transcriptional functionality of ERα may either be promoted or decreased by gene products of HPV. Hormonal treatment is frequently administered to patients with hormone-sensitive recurring or metastatic gynecologic malignancies, although response rates and therapeutic outcomes are inconsistent. Therefore, this review outlines the use of hormonal therapy for gynecological cancers and identifies the current knowledge gaps.
  • No Thumbnail Available
    Item
    Monkeypox Outbreak 2022: What We Know So Far and Its Potential Drug Targets and Management Strategies
    (PubMed Central Press, 2023-01-15) Rabaan, Ali A; Abas, Abdul Hawil; Tallei, Trina Ekawati; Al-Zaher, Mona A; Al-Sheef, Noor M.; Fatimawali; Al-Nass, Esraa Z; Al-Ebrahim, Eba A; Effendi, Yunus; Idroes, Rinaldi; Alhabib, Mather F.; Al-Fheid, Hussain A.; Adam, Ahmad Akroman; Emran, Talha Bin
    Monkeypox is a rare zoonotic disease caused by infection with the monkeypox virus. The disease can result in flu-like symptoms, fever, and a persistent rash. The disease is currently spreading throughout the world and prevention and treatment efforts are being intensified. Although there is no treatment that has been specifically approved for monkeypox virus infection, infected patients may benefit from using certain antiviral medications that are typically prescribed for the treatment of smallpox. The drugs are tecovirimat, brincidofovir, and cidofovir, all of which are currently in short supply due to the spread of the monkeypox virus. Resistance is also a concern, as widespread replication of the monkeypox virus can lead to mutations that produce monkeypox viruses that are resistant to the currently available treatments. This article discusses monkeypox disease, potential drug targets, and management strategies to overcome monkeypox disease. With the discovery of new drugs, it is hoped that the problem of insufficient drugs will be resolved, and it is not anticipated that drug resistance will become a major issue in the near future.